Cytokinetics’ candidate for treating ALS failed a Phase III trial. At a second interim analysis of the trial, an independent review committee recommended that Cytokinetics discontinue its COURAGE-ALS trial for reldesemtiv. (Endpoints News)
The stage has been set for generic drugs as the Biden administration asked the Supreme Court to hear the skinny labels case between GSK and Teva. The U.S. Solicitor General said Teva’s generic version of GSK’s heart drug Coreg could not have violated GSK’s patent rights because Teva omitted the infringing use of the drug from its labeling. (Benzinga)
Eli Lilly said remternetug, its experimental Alzheimer’s drug, reduced amyloid in a small study. The Indianapolis-based drugmaker is launching a Phase III study of the experimental antibody. (Seeking Alpha)
The European Medicines Agency recommended expanding the use of Novo Nordisk’s weight loss drug Wegovy in adolescents aged 12 years and older. The company did not indicate a timeline for its plans to launch the drug, already available in Denmark and Norway, in other EU countries. (Reuters)
A group of pharmacy startups set out to make it easier for patients to get their prescriptions and landed heaps of venture capital cash to do it. Now, the cracks in their business models are starting to show. Startups are cutting employees and limiting their ambitions as the low-margin business model clashes with the high-growth culture of venture capital. (Business Insider)
